Disparities in testicular cancer incidence, mortality, and place of death trends from 1999 to 2020: A comprehensive cohort study

• Published in: Cancer reports Vol. 6; no. 10; p. e1880
• Main Authors: Gold, Beck O, Ghosh, Anushka, Goldberg, Saveli I, Chino, Fumiko, Efstathiou, Jason A, Kamran, Sophia C
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01-10-2023; John Wiley and Sons Inc; Wiley
• Subjects: Age groups; Censuses; Cohort Studies; Cross-Sectional Studies; Disease control; Ethnicity; Health facilities; Hispanic people; Humans; Incidence; Male; Marital status; Medical prognosis; Metastasis; metastatic neoplasm; Mortality; Neoplasms, Second Primary; Original; place of death; Population; Race; Regression analysis; Retrospective Studies; Testicular cancer; Testicular Neoplasms - epidemiology; Trends; United States - epidemiology; Urbanization; White people; United States; United States > US; testicular cancer; mortality; place of death; incidence; metastatic neoplasm
• ISSN: 2573-8348; 2573-8348
• DOI: 10.1002/cnr2.1880

Testicular cancer (TC) mortality rates have decreased over time, however it is unclear whether these improvements are consistent across all communities.
The aim of this study was to analyze trends in TC incidence, mortality, and place of death (PoD) in the United States between 1999-2020 and identify disparities across race, ethnicity, and geographic location.
This cross-sectional study used CDC WONDER and NAACCR, to calculate age-adjusted rates of TC incidence and mortality, respectively. PoD data for individuals who died of TC were collected from CDC WONDER. Using Joinpoint analysis, longitudinal mortality trends were evaluated by age, race, ethnicity, US census region, and urbanization category. TC stage (localized vs metastatic) trends were also evaluated. Univariate and multivariate regression analysis identified demographic disparities for PoD. A total of 8,456 patients died of TC from 1999-2020. Average annual percent change (AAPC) of testicular cancer-specific mortality (TCSM) remained largely stable (AAPC, 0.4; 95% CI -0.2 to 0.9; p = 0.215). Men ages 25-29 experienced a significant increase in TCSM (AAPC, 1.3, p = 0.003), consistent with increased metastatic testicular cancer-specific incidence (TCSI) trend for this age group (AAPC, 1.6; p < 0.01). Mortality increased for Hispanic men (AAPC, 1.7, p < 0.001), with increased metastatic TCSI (AAPC, 2.5; p < 0.001). Finally, younger (<45), single, and Hispanic or Black men were more likely to die in medical facilities (all p < 0.001). The retrospective study design is a limitation.
Significant increases in metastatic TC were found for Hispanic men and men aged 25-29 potentially driving increasing testicular cancer specific mortality in these groups. Evidence of racial and ethnic differences in place of death may also highlight treatment disparities.